InMode Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" InMode stock.
View analyst ratings for InMode or view top-rated stocks.

Wall Street analysts have given InMode a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InMode wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

InMode saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,990,000 shares, an increase of 17.8% from the May 13th total of 1,690,000 shares. Based on an average daily trading volume, of 669,800 shares, the short-interest ratio is currently 3.0 days. Approximately 8.2% of the company's stock are sold short.
View InMode's Short Interest.

InMode is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for InMode.

InMode Ltd. (NASDAQ:INMD) posted its quarterly earnings results on Wednesday, May, 5th. The healthcare company reported $0.69 EPS for the quarter, topping the Zacks' consensus estimate of $0.41 by $0.28. The healthcare company earned $65.52 million during the quarter, compared to analysts' expectations of $51.14 million. InMode had a net margin of 41.20% and a trailing twelve-month return on equity of 38.62%. The company's quarterly revenue was up 62.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.30 earnings per share.
View InMode's earnings history.

InMode's stock was trading at $24.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INMD shares have increased by 277.3% and is now trading at $92.05.
View which stocks have been most impacted by COVID-19.

InMode issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided EPS guidance of 2.600-2.750 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.500. The company issued revenue guidance of $270 million-$280 million, compared to the consensus revenue estimate of $264.47 million.

5 Wall Street analysts have issued 1-year target prices for InMode's stock. Their forecasts range from $84.00 to $104.00. On average, they expect InMode's share price to reach $93.80 in the next year. This suggests a possible upside of 1.9% from the stock's current price.
View analysts' price targets for InMode or view top-rated stocks among Wall Street analysts.

1 employees have rated InMode CEO Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among InMode's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to InMode include Getinge (GNGBY), LivaNova (LIVN), CONMED (CNMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), ViewRay (VRAY), TransMedics Group (TMDX), Cutera (CUTR), AxoGen (AXGN), Semler Scientific (SMLR), Stereotaxis (STXS), Zynex (ZYXI), Edap Tms (EDAP) and Second Sight Medical Products (EYES).
View all of INMD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

InMode trades on the NASDAQ under the ticker symbol "INMD."

InMode's stock is owned by a number of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (4.95%), William Blair Investment Management LLC (2.20%), Renaissance Technologies LLC (1.52%), Standard Life Aberdeen plc (1.44%), Morgan Stanley (1.43%) and Thrivent Financial for Lutherans (1.39%).

INMD stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Miura Global Management LLC, Noked Israel Ltd, Prospect Capital Advisors LLC, Point72 Asset Management L.P., Wasatch Advisors Inc., Loomis Sayles & Co. L P, and Victory Capital Management Inc..

INMD stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, William Blair Investment Management LLC, Thrivent Financial for Lutherans, Migdal Insurance & Financial Holdings Ltd., Standard Life Aberdeen plc, Fred Alger Management LLC, Morgan Stanley, and Man Group plc.

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INMD stock can currently be purchased for approximately $92.05.

InMode has a market capitalization of $2.94 billion and generates $206.11 million in revenue each year. The healthcare company earns $75.03 million in net income (profit) each year or $1.78 on an earnings per share basis.

InMode employs 311 workers across the globe.

The official website for InMode is www.inmodemd.com.

InMode is headquartered at TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200.

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]